No increased risk of coronary heart disease for patients receiving androgen deprivation therapy for prostate cancer in Chinese/Taiwanese men

• Published in: Andrology (Oxford) 2016-01, Vol.4 (1), p.128-132
• Main Authors: Wang, L. H., Liu, C. K., Chen, C. H., Kao, L. T., Lin, H. C., Huang, C. Y.
• Format: Article
• Language: English
• Subjects: Aged; Androgen Antagonists - adverse effects; Androgen Antagonists - therapeutic use; androgen deprivation therapy; Cohort Studies; Coronary Disease - epidemiology; coronary heart diseases; epidemiology; Humans; Male; Proportional Hazards Models; Prostatic Neoplasms - drug therapy; Prostatic Neoplasms - epidemiology; Retrospective Studies; Risk Factors; Taiwan - epidemiology
• ISSN: 2047-2919; 2047-2927
• DOI: 10.1111/andr.12141

Summary The relationship between androgen deprivation therapy (ADT) and coronary heart disease (CHD) remains controversial. Furthermore, the majority of such studies focused on Caucasian populations, and there is still a paucity of studies among Asian populations. This population‐based study aimed to investigate the relationship between ADT and CHD in an ethnic Chinese (i.e., Taiwanese) population. We used data sourced from the Taiwan ‘Longitudinal Health Insurance Database'. This study included 1278 patients with prostate cancer in the study group and 1278 subjects without prostate cancer in the comparison group. Each patient was individually tracked for a 3‐year period to identify those who had subsequently received a diagnosis of CHD. The results showed that the incidence rate of CHD during the 3‐year follow‐up period was 4.69 (95% CI: 2.99–5.48) per 100 person‐years and 2.67 (95% CI: 2.15–3.27) per 100 person‐years for the study and comparison cohort, respectively. The Cox proportional hazard regression showed that the hazard ratio for CHD during the 3‐year follow‐up period for prostate cancer patients was 1.65 (95% confidence interval (CI) = 1.25–2.16) compared with comparison subjects after adjusting for patients' geographic location, monthly income, urbanization level, hypertension, diabetes, hyperlipidemia, and stroke. However, we failed to find a significant difference in the adjusted hazard of CHD during the 3‐year follow‐up period between prostate cancer patients who did and those who did not receive ADT (hazard ratio = 1.12, 95% CI = 0.79–1.59). We concluded that prostate cancer but not ADT was significantly associated with CHD. In addition, a common cause of prostate cancer and coronary heart disease could exist.